Exploring the relationship between antipsychotic and metabolic complications in individuals with newly diagnosed schizophrenia and other psychotic and mood disorders: a study on dyslipidemia and hyperglycemia induction.

Objective: To identify the relationship between statins and metabolic disorders when used as antipsychotics or combined with anti-psychotic medication in newly diagnosed Individuals diagnosed with schizophrenia and other psychiatric conditions are characterized
by disturbances in mood or psychosis.

Method: We used electronic medical records and file records from Jordan University Hospital, King Abdullah University Hospital, and the National Center of Mental Health to conduct a matched case-control analysis. Patients between the ages of 20 and 55, suffering from schizophrenia, bipolar disorder (BD), and any form of affective psychosis, underwent continuous treatment with antipsychotics or statins, also known as psychotic therapy, for a duration of 4 to 6 months using the same medication.

Result: We matched a total of 986 incident cases of metabolic syndrome to 1678 control subjects. The study examined the effects of medication on metabolic disorders. The risk of metabolic syndrome was significantly higher for people who took olanzapine (odds ratio: 4.42, 95% CI: 3.73–5.23) and risperidone (odds ratio: 5.17, 95% CI: 4.15–6.44). On the other hand, the risk of metabolic syndrome was low for people who took quetiapine. The odds ratio for aripiprazole is 0.081 with a 95% confidence interval of 0.04–0.16. The odds ratio for statins is 0.27 with a 95% confidence interval of 0.18–0.40. The odds ratio for the other variable is 0.02 with a 95% confidence interval of 0.01–0.04.
Conclusions: Since statins have been used as a psychotic medication for mood disorder symptoms, it was found that all mood disorder patients who received statins did not have any metabolic disorder symptoms.